MCM
LBPH

Moore Capital Management’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History

Moore Capital Management’s Portfolio LBPH Stock Details LBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-45,728
Closed -$254K – 618
2023
Q3 		$254K Hold
45,728
– – ﹤0.01% 365
2023
Q2 		$336K Buy
+45,728
New +$346K 0.01% 361

Other funds holding LBPH

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Moore Capital Management's LBPH Position: Q4 2023 in Review

Moore Capital Management sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q4 2023, closing a stake of 45,728 shares — an estimated $254K sold.

Moore Capital Management first reported a position in LBPH in Q2 2023 and held it in 2 quarters. The position peaked at $336K in Q2 2023. 52 funds tracked by Wall St. Rank hold LBPH as of Q4 2023.

  • Moore Capital Management reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Moore Capital Management sold 45,728 Longboard Pharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $254K.
  • Moore Capital Management first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q2 2023 and held it in 2 quarters.
  • Moore Capital Management's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $336K in Q2 2023.
  • 52 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Moore Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.